SCHEDULE: Armistice Capital Acquires 9.99% Stake in IceCure Medical

Armistice Capital, LLC and Steven Boyd have jointly reported beneficial ownership of 300,332 ordinary shares, representing 9.99% of IceCure Medical Ltd., as of June 30, 2026.

Summary

• Armistice Capital, LLC and Steven Boyd have filed a Schedule 13G, indicating they collectively beneficially own 300,332 ordinary shares of IceCure Medical Ltd.
• This ownership stake represents 9.99% of the company's outstanding ordinary shares.
• The filing date for this event is June 30, 2026.
• Armistice Capital, LLC acts as the investment manager for the Master Fund, which is the direct holder of these shares.
• Steven Boyd is the managing member of Armistice Capital, LLC.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, indicating a significant but not controlling stake acquisition by an investment firm, which could signal confidence in the company's future prospects.

Positives

• Significant stake acquisition by an investment firm (Armistice Capital) suggests potential confidence in the company's value or future growth.
• The 9.99% ownership is a substantial minority stake, indicating a notable investor presence.

Negatives

• The filing does not detail the reasons for the acquisition or any specific strategic intentions beyond standard investment management.
• The Master Fund disclaims beneficial ownership due to the investment management agreement, which is a standard but complex ownership structure.

Risks

• Potential for increased market volatility if Armistice Capital decides to significantly alter its position.
• The filing does not provide forward-looking statements regarding the company's performance or Armistice Capital's intentions.

Future Outlook

No specific future outlook or guidance is provided in this Schedule 13G filing.

Management Comments

• Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.
• The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment firms, as reported in Schedule 13G filings, are common in the healthcare technology sector. Such filings often precede or coincide with strategic shifts or increased investor scrutiny.

Stakeholder Impact

• Shareholders may see increased interest in the stock due to the significant investment by Armistice Capital.
• The market may interpret this acquisition as a sign of potential value or upcoming strategic changes, influencing investor sentiment.

Next Steps

• Continued monitoring of Armistice Capital's stake and any subsequent filings or disclosures.
• Observation of any strategic actions or communications from IceCure Medical Ltd. in light of this new significant shareholder.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While the acquisition of a significant stake by an investment firm can be a positive signal, the filing itself lacks specific strategic details or performance metrics. It indicates a substantial investor presence but does not provide enough information to warrant a buy or sell recommendation without further context on the company's performance and the investor's intentions.

Keywords

IceCure Medical, Armistice Capital, Schedule 13G, Ordinary Shares, Beneficial Ownership, Investment Management